Artimplant USA Medical Advisory Board

Artimplant has formed a Medical Advisory Board (MAB) in the US comprising leading surgeons with a diversity of expertise in the field of orthopedic and podiatric medicine. The MAB will provide feedback and guidance to Artimplant and develop knowledge of Artimplant's products.

The members of the Artimplant USA Medical Advisory Board (MAB) are: Eric Giza, MD, Edward Diao, MD, Joseph M. Berman, MD, Janos P. Ertl MD, Wayne Gersoff MD, Keith Jacobson, DPM, Jason R. Miller, DPM and Lars Peterson, PhD, MD. A closer presentation of the MAB members can be found on Artimplant's website www.artimplant.com/about-us.

“The Medical Advisory Board’s collective expertise, insights and real-world clinical experience will be instrumental as we continue to grow,” said Kjell Thörnbring, CEO, Artimplant AB. “We are honored to have assembled such an impressive group of key opinion leaders who will help us increase the knowledge about the use of our products in the US market.”

For further information, please contact:
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 119 025

Further information is available at www.artimplant.com where you can also subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedics. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet as well as shoulder and other soft tissue injuries.

Artimplant is a public company, listed on NASDAQ OMX Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting on the Company's business, including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information that Artimplant will make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on November 27, 2012 at 1 pm (Swedish time).

About Us

Artimplant is a research- and development company, active within bio-materials.